-
Mashup Score: 0Drug Development Dashboard - Friends of Cancer Research - 2 year(s) ago
Friends has created a series of interactive dashboards as a tool to gain data driven insights into the landscape of oncology drug development and FDA drug approvals. The data in these dashboards are compiled from online publicly available data sources and are regularly updated. Dashboard Functionality Hover your mouse over the figures on the dashboards…
Source: Friends of Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Combined arginine depletion, GCN2 kinase inhibition, and senolytic therapy reduces HCC growth.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read this week's Cancer Discovery #ResearchWatch, Arginine Depletion plus GCN2 Inhibition Sensitizes HCC Cells to Senolytic #Therapies, summarizing the work of Rindert Missiaen, Nicole M Anderson, M Celeste Simon et al. https://t.co/kG80syVCYw @PennCancer https://t.co/K4C0IJmUd5
-
-
Mashup Score: 4Project FrontRunner - 2 year(s) ago
Advancing Development of New Oncology Therapies to the Early Clinical Setting
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New web page: OCE #ProjectFrontRunner: Advancing development of new #oncology #therapies to the early clinical setting. #drugdevelopment https://t.co/RF4LmhXslR
-
-
Mashup Score: 2Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New study: pancreatic tumors with low levels of Gα13 expression increased mTOR signaling, & targeting the mTOR pathway reduced #tumor growth. It showed some #PDAC patients may benefit from #therapies inhibiting the mTOR signaling pathway: https://t.co/9lCjvYKcv3 #pancreaticcancer https://t.co/iIvOByLdCX
-
-
Mashup Score: 0Project FrontRunner - 2 year(s) ago
Advancing Development of New Oncology Therapies to the Early Clinical Setting
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Learn about one of the newest OCE projects, #ProjectFrontRunner: Advancing development of new #oncology #therapies to the early clinical setting #drugdevelopment https://t.co/RF4LmhFQXh
-
-
Mashup Score: 2Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New study: pancreatic tumors with low levels of Gα13 expression increased mTOR signaling, & targeting the mTOR pathway reduced #tumor growth. It showed some #PDAC patients may benefit from #therapies inhibiting the mTOR signaling pathway: https://t.co/9lCjvYKcv3 #pancreaticcancer https://t.co/4w7gDDXpgq
-
-
Mashup Score: 2Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New study: pancreatic tumors with low levels of Gα13 expression increased mTOR signaling, & targeting the mTOR pathway reduced #tumor growth. It showed some #PDAC patients may benefit from #therapies inhibiting the mTOR signaling pathway: https://t.co/9lCjvYKcv3 #pancreaticcancer https://t.co/b9yyB86PGC
-
-
Mashup Score: 0
UK Medical Research Council, NIHR Biomedical Research Centre at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, and Wellcome Trust.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
Risk of severe #COVID-19 #outcomes associated with #immune- #mediated #inflammatory #diseases and #immune- #modifying #therapies: a nationwide cohort study in the #OpenSAFELY platform https://t.co/YGr8NhYmVK https://t.co/0Mwg8TDvcQ
-
-
Mashup Score: 7Cancer Therapy Approval Timings in the US and Europe, 2010-2019 - 2 year(s) ago
This cross-sectional study compares market authorization dates for new oncology therapies approved in the US and Europe from 2010 to 2019 and examines and contrasts the regulatory activities in the approval of new cancer medicines.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
New #cancer #therapies are approved earlier in the USA vs Europe. The median delay in market authorization for new oncology therapies in Europe was 241 (150-370) days compared with the US. https://t.co/ixrPYWbtja https://t.co/aQBUvWeNxL
-
-
Mashup Score: 2Virtual Reality Therapies: Funding & Payment Considerations in the US - VR for Health - 2 year(s) ago
Authors Hélène Louys and Pol-Antoine Hamon describe the funding framework for commercializing VR solutions in the United States.
Source: VR for HealthCategories: Healthcare Professionals, Latest HeadlinesTweet-
🙏🏼 Helene Louys and @hamon_pol for the new @vrforhealth article on #funding considerations for #virtualreality #vr #therapies and #treatment in the #USA 👏🏼@xr_health ✅ https://t.co/9VrPBmBOgx #eHealth #HealthTech #xr #CPT #coding https://t.co/XHLEAOMfrg
-
98.4% of original #oncology approvals were approved on or ahead of their PDUFA goal date, indicating timelines established through #PDUFA help support timely and predictable access to new oncology #therapies. Explore #FriendsDashboard https://t.co/CWQX4YOxiq https://t.co/Dbel8ZncuS